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ral  rotavirus  vaccines  have  yielded  different  point  estimates  of  efﬁcacy  when  tested  in different  populations.  While  population  and  environmental  factors
ay  account  for  these  differences,  study  design  characteristics  should  also be considered.  We  review  the  study  design  elements  of  rotavirus  vaccine  trials
hat  may  affect  point  estimates  of  efﬁcacy,  and  propose  a  framework  for evaluating  new  rotavirus  vaccines.
© 2014 Published  by  Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).The World Health Organization (WHO) has recommended oral
otavirus vaccines for all infants worldwide [1]. As of May  20,
014, 60 countries worldwide and 26 GAVI-eligible countries had
ntroduced rotavirus vaccine (RV) into their national immunization
rograms [2]. (Fig. 1) Major barriers to more rapid introduction
f rotavirus vaccines in low-resource settings have been related
o vaccine cold chain constraints in some countries and limited
roduct-of-choice availability for others. Thus, the availability
f additional, affordable rotavirus vaccines is a high priority to
nhance rotavirus disease control efforts.
Clinical trials under real-world conditions in low-resource
ountries established the public health beneﬁt of RotaTeq® (Merck
 Co.) and Rotarix® (GlaxoSmithKline), and informed the WHO
ecommendation for their use [1,3–5]. Much has been written
bout the lower point estimates of efﬁcacy in these trials compared
ith trials performed in higher resource settings. Among the rea-
ons given for the lower efﬁcacy are higher maternal antibody in
ow-resource settings, environmental enteropathy, differences in
he gut microbiome among children in different resource settings,
utritional status, breastfeeding practices and interference by oral
oliovirus vaccines [6–9]. In addition to these factors, we propose
hat the contribution of study design differences should be con-
idered when comparing point estimates of efﬁcacy across trials.
n addition, the biologic factors and study design factors may be
nterrelated; for example, the higher antibody in low resource sett-
ngs may  be due to both an increased exposure to rotavirus and to
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8121, USA. Tel.: +1 206 285 3500; fax: +1 206 825 6619.
E-mail address: kneuzil@path.org (K.M. Neuzil).
ttp://dx.doi.org/10.1016/j.vaccine.2014.04.074
264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC Bthe younger age at administration of routine childhood vaccines,
including rotavirus vaccines.
Currently, there is no accepted correlate of protection for
rotavirus vaccines, and thus development of new rotavirus vaccines
for the foreseeable future will likely require evaluations of clinical
efﬁcacy. Recently, a new rotavirus vaccine, ROTAVAC®, based on the
116E rotavirus strain and manufactured by Bharat Biotech Interna-
tional Limited of India, demonstrated efﬁcacy in a pivotal clinical
trial in India [10,11]. Additional rotavirus vaccines are in various
stages of preclinical and clinical development. The parameters for
the success of such trials from a regulatory perspective will likely
differ from the parameters for policy or vaccine introduction deci-
sions, and thus the various study designs used to evaluate efﬁcacy
in these trials are likely to differ.
To properly frame the results of clinical trials conducted with
new vaccines, we reviewed the available literature on efﬁcacy tri-
als of rotavirus vaccines in low-resource settings in Africa and Asia.
While acknowledging the importance of safety in regulatory and
policy decisions, we  limited this review to efﬁcacy outcomes, and
to the currently approved and recommended vaccines (Rotarix®,
RotaTeq®). Both Rotarix® and RotaTeq® were already approved
by international regulatory authorities when tested in Africa and
Asia, and thus those trials were conducted primarily to inform
policy.
Under the assumption that aspects of study design and popu-
lation characteristics will inﬂuence the point estimates of efﬁcacy
obtained, we propose that comparisons of point estimates of efﬁ-
cacy from different trials may  be challenging, and should be done
with a clear understanding of trial design and the variables that
could inﬂuence such comparisons. Table 1 provides a number of fac-
tors that are known or hypothesized to inﬂuence rotavirus vaccine
immunogenicity and/or efﬁcacy, with references and examples
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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mFig. 1. Rotavirus vaccine introductions
rom clinical trials. We  then used these study design characteristics
s a framework for evaluating the efﬁcacy data from the new oral
otavirus vaccine, ROTAVAC® as an example of how to interpret
ppropriately new efﬁcacy results (Table 2).
Concomitant administration of oral poliovirus vaccines (OPV)
ith oral rotavirus vaccines reduces the immunogenicity of
otavirus vaccines, as measured by serum IgA antibody responses
nd rotavirus vaccine shedding, when compared with administra-
ion of the two vaccines separated in time by 1–2 weeks (Table 1)
12–14]. This lower immunogenicity would be expected to result
n no effect, or a reduction in efﬁcacy, against clinical outcomes. In
oderate to high resource settings, rotavirus vaccines were admin-
stered with inactivated poliovirus vaccines (IPV), or separated
rom OPV administration by at least 2 weeks. In trials performed
o date in low resource settings, most of the children received OPV
oncomitantly with RVs as shown in Table 2. The exception was
he trial of RotaTeq® in Africa, where only 35% of children received
PV with RV. In this example, however, the administration was
ot separated by two weeks, but may  have been separated by only
 day or two. The effect of OPV in that situation is not known, but
ight be expected to be even greater than concomitant adminis-
ration given the replication kinetics of OPVs. Overall, the global
lans to move from trivalent to bivalent OPVs, and eventually to
nactivated poliovirus vaccines (IPV) would be expected to have
avorable effects on the immunogenicity of oral RVs in low-resource
ettings.
A major issue emerging from rotavirus vaccine trials in high
ortality/low resource settings compared with low mortality/highVI-eligible countries as of May  1, 2014.
resource settings has been the observation of possible waning
of efﬁcacy in the second year of life. Thus, in developing world
trials that include follow-up time beyond the ﬁrst year of life
(or over multiple years) the relative person-time accumulated
estimate reported during the ﬁrst versus second year of life is crit-
ical to interpreting the summary point estimate of efﬁcacy. For
example, the RotaTeq® trial in Africa ended on a speciﬁc date, and so
the primary outcome included follow-up to a median of 21 months
of age [5]. Thus, the overall efﬁcacy reported in this trial reﬂects
cases occurring at various ages. Relatively more cases during the
ﬁrst year of life when vaccine protection appears to be highest
would lead to higher overall cumulative efﬁcacy. Additionally, sites
had different follow-up time and contributed cases differently to
the ﬁrst versus second years of life. In the RotaTeq® study in Africa,
for example, the site in Mali, with lower point estimates of efﬁ-
cacy during both years, contributed relatively more cases in the
second year of life as compared with the ﬁrst year. So comparisons
of efﬁcacy beyond the ﬁrst year of life are particularly problematic
without a full understanding of the mix  of cases by year and by site
[15,16].
Another important element to consider when comparing
results from different trials is the outcome measure. Most tri-
als have focused on severe gastroenteritis as measured by the
Vesikari scoring system, as the primary outcome measure. Even
in circumstances where the outcome is relatively uniform, how
the scoring system is utilized may  differ between sites [17]. In
addition, secondary outcome measures (e.g. efﬁcacy according to
severity of disease, all-cause gastroenteritis) may offer additional
K.M. Neuzil et al. / Vaccine 32S (2014) A179–A184 A181
Table  1
Effect of study design and population characteristics on estimates of point efﬁcacy in rotavirus vaccine trials.
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Table 1 (Continued ).
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iOral polio vaccine.
Gastroenteritis.
Oral rehydration solution.
nformation on the public health value of a vaccine, but also require
nterpretation of point estimates in the context of the deﬁnitions
mployed. For example, in rural Kenya, multiple measures of
evere gastroenteritis were used for children in the trial as a
ubstudy of the larger multicenter RotaTeq® efﬁcacy trial in Africa
18]. The primary outcome measure for the multicenter trial was
evere gastroenteritis as measured in healthcare facilities using
he 20-point modiﬁed Vesikari scoring system. A second measure
f acute gastroenteritis was employed during weekly home visits,
sing WHO’s Integrated Management of Childhood Illness (IMCI)
riteria for dehydration. RotaTeq® was 83.4% (95% CI 25.5, 98.2)
fﬁcacious in the ﬁrst year of life against severe rotavirus gastroen-
eritis (Vesikari score ≥ 11) and 34.4% (95% CI 5.3, 54.6) efﬁcacious
n preventing acute gastroenteritis associated with severe dehy-
ration in the home setting. These differences highlight the need
o critically evaluate the degree to which outcome measures and
he tools to measure them are tuned to the population being
tudied.
The preceding example also illustrates why comparisons of
oint estimates of efﬁcacy alone provide an incomplete assessment
f vaccine performance. Absolute disease rates and case reductions
re more relevant measures of the public health impact of vaccines.
his concept was endorsed by an international panel of experts
onvened in 2007, prior to the release of data from the rotavirus
accine trials in developing countries [19]. Using the example above
n Kenya, rotavirus vaccines prevented an estimated 3.3 cases per
00 child-years of severe rotavirus gastroenteritis, as deﬁned by
he Vesikari score and measured at health facilities, and 19 cases
er 100 child-years of acute gastroenteritis with severe dehydra-
ion as deﬁned by IMCI criteria and measured in the home [18].
his illustrates the importance of outcome deﬁnition, both from the
erspective of comparisons, but also from the perspective of public
ealth value. In rural Africa, prevention of home cases of dehydra-
ion may  be a more relevant measure of prevention as children have
imited access to care, and thus the use of different outcome deﬁni-
ions can provide a more complete assessment of disease reduction
fforded by vaccines [18]. It will be important to report incidence
ates in placebo and vaccine groups for a number of outcomes in tri-
ls of new rotavirus vaccines, again with an understanding of how
ifferences in case ascertainment and case deﬁnition could affect
hose incidence rates.
Age is an important inﬂuencer of vaccine immunogenicity, with
mmune responses to vaccine generally improving with age. It
s difﬁcult to determine whether the lower immune responsesreﬂect an immature immune system, or interference by high con-
centrations of maternal antibody that wane over time. What is
known is that the high levels of serum neutralizing antibody against
the human rotavirus serotypes in the RotaTeq® vaccine measured
before vaccination, and thus presumed to be maternal antibody,
has only been observed in the low resource settings of Africa and
Asia [9].
Additional factors that could impact point estimates of efﬁcacy
are shown in Table 1. Some are difﬁcult to quantify, and a full
description of each of these parameters may not always be provided
in published manuscripts. For example, while pivotal studies for
licensure generally have strict inclusion criteria, the Rotarix® and
RotaTeq® trials in Africa and Asia had more lenient inclusion
criteria. While one would expect healthier children to have bet-
ter immune responses than children with underlying disease, few
speciﬁc data are available. The limited studies performed in HIV-
infected children suggest a satisfactory immune response [3,19].
Another example is the routine use of interventions, such as oral
rehydration solution (ORS) that could affect the outcome of inter-
est – severe rotavirus gastroenteritis – and potentially mask the full
effects of the vaccine on severe disease [21].
Likewise, the timing of vaccination and the method of analysis
in relation to rotavirus circulation may  affect efﬁcacy estimates,
although the direction of the effect may  be difﬁcult to predict.
For example, in the efﬁcacy trial in the South Africa site, all
vaccinations were completed prior to the start of the rotavirus
season. Thus, children exposed to rotavirus had received vaccine
relatively recently, which may favor vaccine efﬁcacy estimates if
there is any waning of immunity over time. In the same trial, at the
Malawi site, vaccinations occurred throughout the year, including
time periods when rotavirus circulated. These differences are
reﬂected in the percentage of children in the placebo group with
detectable rotavirus IgA antibody at 18 weeks of age at the two
sites – 40.5% in Malawi as compared to 11.6% in South Africa.
Another example is the RotaTeq® trial that included a cohort in
Mali, where vaccinations were given before and during rotavirus
season. As the per protocol deﬁnition required cases to occur at
least 2 weeks following the last dose of vaccine, fewer cases were
available for the per protocol evaluation. The intention to treat
analysis is arguably the more relevant from the public health
perspective, as rotavirus vaccines are given with other childhood
vaccines on a year-round schedule. The use of the PP deﬁnition has
led many to conclude that the vaccine was not efﬁcacious in Mali
[22]. While both the ITT and PP point estimates are imprecise due
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Table 2
Summary of efﬁcacy trials of currently approved rotavirus vaccines in low-resource settings in Africa and Asia.
Africa
Concomitant
OPVa use (%)
Median age
(weeks)
Randomization Outcome measures Number
of doses
Sites Other Efﬁcacy (follow-up to 1
year of age) (95% CI)
Efﬁcacy (second
year of life) (95% CI)
RotaTeq® 35 7, 12, 16 Individual Severe rotavirus GEb
(Vesikari ≥ 11)
3 Ghana, Kenya,
Mali [5]
65% birth dose
OPV
64.2% (40.2–79.4) 19.6% (−15.7–44.4)
Rotarix® 99 6, 11, 16 Individual Severe rotavirus GE
(Vesikari ≥ 11)
2 Malawi, South
Africa [3]
3 dose arm also
included
58.7% (35.7–74.0) Results available by
site [14,15]
Asia
Concomitant
OPV use (%)
Median age
(weeks)
Randomization Outcome measures Number
of doses
Sites Other Efﬁcacy (follow-up to 1
year of age) (95% CI)
Efﬁcacy (follow-up to 2
years of age) (95% CI)
RotaTeq® 95 9, 14, 18 Individual Severe rotavirus GE
(Vesikari ≥ 11)
3 Bangladesh,
Vietnam [4]
51.0% (12.8–71.8) 45.5% (1.2–70.7)
99  8, 13, 17 Individual Severe rotavirus GE
(Vesikari ≥ 11)
3 Bangladesh site
only (Matlab:
icddr,b area)
[4]
25% birth dose
OPV
45.7% (−1.2–71.8) 39.3% (−18.3–69.7)
90%  10, 14, 19 Individual Severe rotavirus GE
(Vesikari ≥ 11)
3 Vietnam only
[4]
No birth dose
of OPV
72.3% (−45.2–97.2) 64.6% (−47.7–93.9)
Rotarix® ∼95 8, 13 Cluster Rotavirus diarrhea presenting
to treatment facility (case
capture identical as to
RotaTeq® trial)
2 Matlab,
Bangladesh
[21]
42.3%c (24–56) n/a
ROTAVAC® 99d 7, 12, 16 Individual Severe rotavirus GE
(Vesikari≥11)
3 Multiple sites
in India [10,11]
56.3% (36.7–69.9) 48.9% (17.4–68.4)
a Oral polio vaccine.
b Gastroenteritis.
c Total effectiveness (direct + indirect).
d Personal communication.
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o the small number of cases that occurred in the ﬁrst year of life,
he ITT point estimate of 42.7% (95% CI −124.7 to 87.7) is more in
ine with the point estimates of efﬁcacy from the sites in Ghana
nd Kenya that were part of that multicenter trial [5]. As we do not
et have a complete understanding of the protective mechanism of
otavirus vaccines in low-resource settings, additional factors that
re not yet understood or easily measured could also affect trial
esults.
In Table 2, realizing that all factors may  not be fully delineated
r reported, the studies of rotavirus vaccines in low-resource sett-
ngs, including the recent results from the ROTAVAC® efﬁcacy trial
onducted in India [10,11], are categorized by important design
haracteristics. For the major variables of age, use of OPV, out-
ome deﬁnition, and type of randomization, the ROTAVAC® efﬁcacy
rial design is similar to the design of the individually random-
zed RotaTeq® and Rotarix® studies. Acknowledging uncertainties
hat may  still remain in the implementation of the study outcome
easurement, differing rotavirus seasonality and epidemiology
etween sites, and other unknown differences between popula-
ions, the point estimates of efﬁcacy from the recently reported
OTAVAC® trial compare quite favorably to those from Rotarix®
nd RotaTeq® trials in low-resource settings. While the RotaTeq®
rial in Asia was designed and conducted as a multicenter trial in
angladesh and Vietnam, we also present the estimates for the two
ites separately, in order to provide what we hypothesize to be
he most relevant comparisons to the ROTAVAC® trial in India. In
he RotaTeq® trial, the point estimates for efﬁcacy against severe
otavirus gastroenteritis in the ﬁrst year of life were 51.0% (95%
I 12.8–73.3) for the entire cohort, 45.7% (95% CI −1.2 to 71.9)
or the Bangladesh cohort and 72.3% (−45.2 to 97.2) for the Viet-
am cohort. The ROTAVAC® point estimate of efﬁcacy for the same
utcome in the ﬁrst year of life was 56.4% (95% CI 36.7–69.9). The
pparent maintenance of efﬁcacy in the second year of life in the
OTAVAC® trial is encouraging, and similar to what was seen in the
otaTeq® trial in Asia, recognizing that point estimates of efﬁcacy
n the second year of life are less precise, given the smaller number
f outcomes.
This is indeed an exciting time for rotavirus vaccines. Ultimately,
ultiple safe and efﬁcacious choices should allow for optimal
rice and supply conditions, resulting in maximal numbers of chil-
ren vaccinated. Head-to-head comparisons of different vaccines
ould be the best way to control for study design and popula-
ion differences, and may  be more common in the future given the
lobal roll-out of rotavirus vaccines. In the meantime, this proposed
ramework should be useful in comparing efﬁcacy estimates of
ew rotavirus vaccines conducted with placebo controls in various
ettings. We  have proposed important design elements to be con-
idered in those comparisons, including age at receipt of vaccine;
o-administration of other vaccines, most notably OPV; deﬁnition
nd method of ascertainment of outcome measure; inclusion and
xclusion criteria; and the pattern of rotavirus circulation. Ulti-
ately, vaccine choices by individual countries are unlikely to be
ased on efﬁcacy alone, and will include considerations of rotavirus
isease burden, vaccine safety, cost and feasibility.onﬂict of interest
None reported.
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